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How oncogenes modulate the self-renewal properties of cancer-initiating cells is incompletely understood. Activating
KRAS and NRAS mutations are among the most common oncogenic lesions detected in human cancer, and occur in
myeloproliferative disorders (MPDs) and leukemias. We investigated the effects of expressing oncogenic KrasG12D from
its endogenous locus on the proliferation and tumor-initiating properties of murine hematopoietic stem and
progenitor cells. MPD could be initiated by KrasG12D expression in a highly restricted population enriched for
hematopoietic stem cells (HSCs), but not in common myeloid progenitors. KrasG12D HSCs demonstrated a marked in
vivo competitive advantage over wild-type cells. KrasG12D expression also increased the fraction of proliferating HSCs
and reduced the overall size of this compartment. Transplanted KrasG12D HSCs efficiently initiated acute T-lineage
leukemia/lymphoma, which was associated with secondary Notch1 mutations in thymocytes. We conclude that MPD-
initiating activity is restricted to the HSC compartment in KrasG12D mice, and that distinct self-renewing populations
with cooperating mutations emerge during cancer progression.
Citation: Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, et al. (2009) Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 7(3): e1000059. doi:10.
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Introduction
Self-renewal is integral to the malignant phenotype [1]. In
principle, the ability of cancer cells to self-renew may be
intrinsic to the compartment in which the tumor-initiating
mutation occurs, or may be acquired as a consequence of
mutations in more differentiated cells. The hematopoietic
system has proven highly informative for addressing how
cancer-associated mutations and cell of origin interact to
establish malignant self-renewing populations. Accumulating
evidence supports the idea that many hematopoietic malig-
nancies exist in a hierarchy of differentiation with only a
minor population capable of propagating and maintaining
the disease in vivo [2]. These cells are termed leukemia-
initiating cells or leukemia stem cells (LSCs), and manifest
some biologic properties of normal hematopoietic stem cells
(HSCs). However, the precise relationship between these
populations is uncertain and appears to depend, in part, on
both the leukemia subtype and on the effects of specific
mutations. For example, overexpressing MLL fusion proteins
found in human acute myeloid leukemia transforms both
murine HSCs and more differentiated progenitors [3,4]. By
contrast, inactivation of the JunB transcription factor must
occur in the HSC compartment for initiation of myeloid
malignancies [5]. These proof-of-concept experiments under-
score the importance of understanding how oncogenes and
tumor suppressors that are commonly mutated in human
cancers perturb self-renewal and growth control. Impor-
tantly, the functional characteristics of LSCs that distinguish
them from HSCs and how these properties are modulated by
oncogenes are poorly understood.
RAS gene mutations are highly prevalent in pancreatic
(.80%), colorectal (40%–50%), endometrial (40%), lung
(30%), and cervical cancers (20%–30%), as well as in myeloid
malignancies (20%–40%) [6]. Of the genes in the canonical
RAS family, KRAS accounts for ;90% of cancer-associated
mutations, whereas HRAS mutations are rare. In hematologic
cancers, NRAS is mutated 2–3 times more often than KRAS
[6]. Cancer-associated RASmutations, which introduce amino
acid substitutions at codons 12, 13, or 61, result in oncogenic
Ras proteins that accumulate in the active, GTP-bound
conformation because of defective guanine nucleotide
hydrolysis [7]. Elevated levels of GTP-bound Ras, in turn,
deregulate signaling in cancer cells by altering the activation
of effector cascades that include the Raf/MEK/ERK, phospha-
tidylinositol 3-kinase (PI3K)/Akt, and Ral-GDS pathways [8].
Chronic and juvenile myelomonocytic leukemias (CMML
and JMML) are aggressive myeloid malignancies that are
classified as myeloproliferative disorders (MPDs) [9]. Both
diseases are characterized by leukocytosis with excess mono-
cytes in blood and bone marrow, and by significant infiltration
of malignant myeloid cells into the liver, spleen, and other
organs. Hyperactive Ras is strongly implicated in the patho-
genesis of JMML and CMML. Somatic NRAS and KRAS
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mutations are found in ;40% of CMML specimens [10,11],
and ;85% of JMML patients have mutations in KRAS, NRAS,
NF1, or PTPN11 (reviewed in [12]). The latter two genes encode
proteins that regulate Ras-GTP levels. Importantly, children
with germline mutations in NF1 or PTPN11 are at markedly
increased risk of developing JMML, which argues strongly that
deregulated Ras signaling can initiate this MPD [12]. This
hypothesis is further supported by studies of Nf1, Kras, and
Ptpn11mutant mice, all of which develop MPDs that resemble
JMML and CMML [13–16]. Mutations that alter other signaling
molecules also cause MPD. For example, the BCR-ABL fusion
gene is the hallmark of chronic myeloid leukemia, and JAK2
mutations are found in nearly all cases of polycythemia vera
(reviewed in [17]). While mutations affecting signaling
molecules are found in nearly all types of MPD, additional
cooperating mutations are rare. MPDs are therefore genet-
ically straightforward and tractable malignancies for under-
standing how aberrant signal transduction contributes to
cancer by perturbation of stem and progenitor cell fates.
Mice expressing oncogenic KrasG12D in hematopoietic cells
develop a fatal MPD with 100% penetrance that is charac-
terized by leukocytosis, splenomegaly, and anemia, with death
at approximately 3 mo of age [13,14]. In this system, injecting
Mx1-Cre, KrasLSL-G12D mice with polyinosinic-polycytidylic
acid (pIpC) induces expression of Cre recombinase, which
removes an inhibitory loxP-STOP-loxP (LSL) element and
activates the KrasG12D allele (we hereafter refer to Mx1-Cre,
KrasLSL-G12D mice that have been treated with pIpC as
KrasG12D mice). Mx1-Cre, KrasLSL-G12D mice provide a robust
experimental system for investigating how expressing onco-
genic Kras from the endogenous promoter affects HSCs and
their progeny in vivo. Here, we identify tumor initiating cells
in the KrasG12D model of MPD and find that, unlike some
myeloid oncogenes, KrasG12D does not confer aberrant self-
renewal properties to committed progenitor cells. However,
small numbers of primitive KrasG12D cells can initiate MPD.
This population shows excessive proliferation and rapidly
dominates multilineage hematopoiesis in vivo. These data
indicate that hyperactive Ras signaling is sufficient for the
competitive advantage demonstrated by mutant HSCs and
further implicate the HSC compartment as critical for
therapy of JMML and CMML. Transplanted KrasG12D HSCs
efficiently initiate T lineage acute lymphoblastic leukemia/
lymphoma (T-ALL), which is associated with Notch1mutations
and with acquisition of LSC activity in differentiating
thymocytes. These results further demonstrate that distinct
self-renewing populations can arise through cooperating
oncogenic mutations during cancer progression.
Results
A Small KrasG12D Population Dominates Both Primitive and
Differentiated Hematopoietic Compartments in Mx1-Cre,
KrasLSL-G12D Mice
Although basal Mx1-Cre activity is low [18,19], many Mx1-
Cre, KrasLSL-G12D mice that are not injected with pIpC
ultimately succumb with MPD ([14] and unpublished data).
This observation suggests that HSCs and/or progenitor cells
that activate KrasG12D expression have a substantial prolifer-
ative advantage in vivo. To assess the kinetics of this process,
we analyzed recombination in the myeloid progenitors of
young Mx1-Cre, KrasLSL-G12D mice that were not treated with
pIpC. Bone marrow cells from 3–5-wk-old animals were
plated in methylcellulose medium to enumerate granulocyte-
macrophage colony forming unit progenitors (CFU-GM), and
individual myeloid colonies were genotyped by PCR. Surpris-
ingly, nearly all CFU-GM in untreated animals were recom-
bined as early as 3 wk of age (Figure 1A). We then examined
more primitive populations in Mx1-Cre, KrasLSL-G12D mice
crossed to a ROSA26 yellow fluorescent protein (YFP)
reporter strain (Figure 1B) [20]. In these mice, cells expressing
Cre are identified by YFP expression. The frequency of YFPþ
cells in wild-type (WT) mice was within the expected range of
background Cre expression [18,19]. However, we found a
much higher incidence of YFP expression in bone marrow
cells of Mx1-Cre, KrasLSL-G12D, ROSA26-YFP mice. This result
was consistent among all populations analyzed, including the
primitive Flk2 Lin/lo Sca1þ c-kitþ (Flk2 LSK) compartment,
which is highly enriched for HSCs [21]. To confirm that YFP
expression correlated with KrasG12D expression, we also
directly genotyped colonies formed by single Flk2 LSK cells.
This method again revealed a predominance of KrasG12D-
expressing cells in naı¨ve Mx1-Cre, KrasLSL-G12D mice (Figure
1C). Together, these data are consistent with an advantage for
Cre-expressing cells in untreated Mx1-Cre, KrasLSL-G12D mice.
Increased Cell Cycle Entry of KrasG12D HSCs
The apparent outgrowth of KrasG12D Flk2 LSK cells in
mice that were not injected with pIpC suggested that KrasG12D
expression might increase proliferation in this compartment.
To test this hypothesis, we stained bone marrow cells
collected from KrasG12D mice and WT littermates 2 wk after
pIpC treatment with antibodies to cell surface proteins and
with dyes that stain DNA and RNA (7-aminoactinomycin D
[7-AAD] and pyronin Y, respectively). These studies revealed
a significant reduction in the number of quiescent Flk2 LSK
cells in KrasG12D animals, which are identified by having a 2n
DNA content and low pyronin Y staining (Figure 2A and 2B).
Whereas the Flk2 subset of WT LSK contains roughly 80%
cells in the G0 phase of the cell cycle, Kras
G12D Flk2 LSK are
only 50% quiescent. As an initial exploration of mechanisms
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Author Summary
Ras proteins act as molecular switches that relay growth signals
from outside the cell. This mechanism is often subverted in cancer,
and Ras proteins are activated directly by RAS gene mutations in
approximately one-third of human malignancies. We have modeled
this in mice engineered to have a Ras mutation. These mice develop
a disease similar to chronic leukemias in humans called myelopro-
liferative disorders. It is marked by a fatal accumulation of mature
and immature cells in the blood and bone marrow. We investigated
whether some or all of these neoplastic cells were immortal. In
agreement with the ‘‘cancer stem cell’’ hypothesis, we found that
immortal cells were extremely rare in the bone marrow of diseased
mice. They were found only in the same cell populations that
contain normal bone marrow stem cells. However, these cells had
high rates of replication and produced large numbers of daughter
cells. Furthermore, many mice went on to develop acute lymphoid
leukemia after acquiring additional mutations in maturing lymphoid
cells. These studies exemplify the evolution of malignant stem cells
during cancer progression. They also highlight the importance of
rare, long-lived cells in the genesis and, potentially, therapy of high-
risk chronic leukemias caused by abnormal Ras proteins.
regulating cell cycle progression, we analyzed D- and E-type
cyclin expression by quantitative PCR in sorted Flk2 LSK
cells from KrasG12D and WT mice. KrasG12D Flk2 LSK cells
had significantly higher expression of cyclin D1 (Figure 2C).
Self-Renewal Is Restricted to Primitive Hematopoietic Cells
in KrasG12D Mice
Bone marrow mononuclear cells from KrasG12D mice
display a hypersensitive pattern of CFU-GM progenitor
growth, which is a cellular hallmark of JMML [12–14]. We
found that this abnormal CFU-GM activity resides primarily
in the common myeloid progenitor (CMP) compartment, and
that these cells demonstrate enhanced proliferation in vivo
([22] and unpublished data). To investigate if this population
could initiate and maintain MPD, we collected Lin/lo Sca1
c-kitþ CD34þ FccRII/III CMPs from 5-wk-old KrasG12D mice
and WT littermates by FACS, and transferred 10,000 of these
cells into lethally irradiated recipients with 106 WT marrow
cells for radioprotective support. Transplanted tester cells,
recipient cells, and support cells were marked by expression
of different isoforms of CD45, allowing them to be
distinguished by flow cytometry. Transplanted KrasG12D or
WT CMPs demonstrated robust day 8 spleen colony-forming
unit (CFU-S8) activity, with colony size somewhat larger for
KrasG12D input CMPs (Figure 3A). However, we detected less
than 0.1% of circulating myeloid cells derived from trans-
planted KrasG12D or WT CMPs 1 mo after transplantation
(Figure 3B and 3C). As expected from previous studies
[23,24], KrasG12D and WT CMPs made minor contributions to
the circulating B cell compartment with a statistically
insignificant trend towards greater B cell production from
KrasG12D cells. Taken together, these data indicate that
KrasG12D CMPs do not initiate a hematologic disease. By
contrast, transferring 500 Flk2 LSK cells from KrasG12D
animals into lethally irradiated recipients rapidly resulted in
durable multilineage reconstitution. KrasG12D cells domi-
nated the T cell and B cell compartments sooner and to a
higher degree than the progeny of WT Flk2 LSK cells in
control animals. The myeloid series demonstrated a more
variable time course, but KrasG12D derived cells also even-
tually out-competed WT cells (Figure 4).
Recipients of KrasG12D Flk2 LSK cells that were euthanized
3 mo after transplantation had mild to moderate MPD,
manifested as leukocytosis and splenomegaly with myeloid
and erythroid infiltration (Figure 5). As discussed below, we
also found that all recipients of KrasG12D Flk2 LSK cells
developed T-ALL 2–4 mo after adoptive transfer. Although
early mortality from T-ALL precluded analyzing recipient
mice beyond 3 mo, KrasG12D Flk2 LSK cells recapitulate the
essential features of MPD seen in the original Mx1-Cre,
KrasLSL-G12D model [13,14].
HSCs Are Less Frequent in KrasG12D Mice but Have
Enhanced Repopulating Ability
We next asked how KrasG12D expression affects HSC
function. Immunophenotypic analysis revealed a 2-fold
reduction in the number of marrow Flk2 LSK cells in
KrasG12D mice 2 wk after pIpC injection (Figure 6A). This was
mostly offset by an increased number of splenic Flk2 LSK
cells. The reduction in marrow Flk2 LSK cells persisted in
older animals (Figure S2). We also performed limit dilution
studies to assess functional HSC activity. In these experi-
ments, lethally irradiated recipients received decreasing
numbers of whole bone marrow cells from either KrasG12D
mice or WT littermates that had been injected with pIpC 2 wk
earlier. Recipients were bled monthly, and flow cytometry was
performed to assess whether CD45.1þ donor cells were able to
provide durable (.2 mo) multilineage (myeloid, B cell, and T
cell) engraftment. These studies demonstrated a striking 10-
fold decrease in the number of long-term repopulating stem
cells in KrasG12D animals compared to the WT littermate
controls (Figure 6B; Table S1).
Progression of MPD despite a reduction in the size of the
HSC compartment suggests an increased production of
mature cells by each KrasG12D HSC. To address this possibility,
we examined the patterns of reconstitution from either
Figure 1. Spontaneous KrasG12D Activation in CFU-GM and HSCs from Mx1-Cre, KrasLSL-G12D Mice
(A) Bone marrow was harvested at 24 d or 5 wk of life from mice that either received a single dose of pIpC at 21 d of life or were left untreated, and
plated in methylcellulose medium with GM-CSF. Individual colonies were isolated and genotyped by PCR to assess for Cre-mediated excision of the LSL
cassette (n¼ 18 colonies from two uninjected animals, and 34 colonies from two injected animals, compiled from two independent experiments; error
bars show SEM).
(B) Mx1-Cre (filled bars) and Mx1-Cre, KrasLSL-G12D (open bars) mice that inherited an LSL-YFP reporter were sacrificed at 5 wk of life, without ever being
injected with pIpC. Expression of YFP requires excision of the LSL cassette from the reporter gene by Cre recombinase. The percentage of YFPþ cells in
all bone marrow cells (Bulk), Lin c-kitþ Sca1myeloid progenitors (MP), LSK cells, and Flk2 LSK cells was assessed by flow cytometry. (n¼ 4 for WT and
for Mx1-Cre, KrasLSL-G12D mice compiled from three independent experiments; error bars show SEM).
(C) Flk2 LSK cells were sorted from bone marrow of 4-wk-old Mx1-Cre, KrasLSL-G12D mice that had not received pIpC, and plated in methylcellulose
medium for a culture period of 14 d. Individual colonies were genotyped by PCR (n¼ 44 colonies from 6 mice in 3 independent experiments; error bar
shows SEM).
doi:10.1371/journal.pbio.1000059.g001
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KrasG12D or WT HSCs in mice that received the limit dilution
dose (13 105 KrasG12D and 13 104 WT bone marrow cells). As
;50% of these recipients were engrafted with donor cells, the
Poisson distribution predicts that approximately 70% of the
engrafting mice received a single HSC and ;24% received
two HSC. By 2 mo after transplantation, donor KrasG12D
marrow cells made a markedly greater contribution to
recipient hematopoiesis than WT cells (Figure 6C).
We were able to compare repopulation of the stem cell
compartment by WT and KrasG12D HSCs in a few lethally
irradiated recipient mice before the onset of T-ALL. In these
experiments, lethally irradiated recipients (CD45.2) were
reconstituted with equal numbers of KrasG12D (CD45.1) and
WT (CD45.1/CD45.2) Flk2 LSK cells, as well as 106 CD45.2
whole bone marrow cells (CD45.2) for radioprotection.
Whereas only one of six recipients euthanized 2 mo after
transplantation showed a clear bias towards KrasG12D-derived
Flk2 LSK cells, mice that survived for 3 mo without evidence
of diffuse T-ALL demonstrated an overwhelming bias
towards KrasG12D-derived Flk2 LSK cells, myeloid progeni-
tors, and mature myeloid cells (Figure S3).
T-ALL Arises from Transplanted KrasG12D HSCs in
Thymocytes That Acquire Somatic Notch1 Mutations
Recipients that were injected with KrasG12D Flk2 LSK cells,
either alone or in a 1:1 ratio with WT Flk2 LSK cells,
uniformly became moribund 8–14 wk after transplantation.
Figure 2. Increased Proliferation of KrasG12D HSC
Bone marrow from 5-wk-old WT and KrasG12D mice was stained with 7-AAD and pyronin Y (PY) for DNA and RNA quantitation, along with surface
markers for Flk2 LSK cells.
(A) Gating is shown for cell cycle analysis of WT and KrasG12D Flk2 LSK cells.
(B) Summary of replicate samples from WT (closed circles) and KrasG12D (open circles) mice (n ¼ 3 or 4 as shown; compiled from two independent
experiments). Means and SEM are WT: G0 81.8 6 4.72, G1 5.66 6 1.76, S-G2-M 11.7 6 2.56; and Kras
G12D: G0 43.6 6 3.19, G1 34.9 6 4.85, S-G2-M 21.4 6
3.14. p-Values by unpaired t-test are indicated: ***, p , 0.001; **, p , 0.01; *, p , 0.05.
(C) RNA from doubly sorted Flk2 LSK cells was isolated, and quantitative PCR performed on cDNA to test expression levels of selected cyclins (n¼3 or 4
as shown; bar shows geometric mean). Results are expressed as fold change in expression compared to WT Flk2 LSK cells, after normalization to b-actin
expression. These results represent three or four independent experiments as shown, each performed with pooled bone marrow from three to five
animals. The geometric mean of cyclin D1 expression is 2.4-fold over WT (95% confidence interval 1.2–4.9). Purity of sorted cells is shown in Figure S1.
doi:10.1371/journal.pbio.1000059.g002
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Examination of euthanized mice revealed massive thymic
enlargement with an arrest in T cell development at the CD4/
CD8 double positive stage, and variable infiltration of blast
cells within the liver, spleen, and bone marrow (Figure 7A).
Importantly, two of three animals from the bone marrow
limit dilution transplantation assay that were engrafted with a
single KrasG12D repopulating unit developed T-ALL that was
identical to that seen in animals repopulated with 500
KrasG12D Flk2 LSK cells (unpublished data).
Next, we asked if T-ALL arose within the bone marrow or
the thymus of mice transplanted with KrasG12D HSCs. To do
this, we took advantage of our prior observation that
recipients conditioned with sublethal irradiation fail to
engraft with KrasG12D bone marrow [13]. Therefore, suble-
thally irradiated recipients can exclusively select for hemato-
logic malignancies with more aggressive biologic behavior. We
isolated bone marrow cells and thymocytes from primary
recipients of KrasG12D Flk2 LSK cells that developed T-ALL,
and injected each population into sublethally irradiated
secondary recipients (Figure 7B). As expected, no animals
demonstrated multilineage engraftment or MPD. Animals
transplanted with thymocytes quickly succumbed with an
identical T-ALL as primary recipients; however, none of the
mice transplanted with bone marrow developed leukemia.
Thus, whereas bone marrow-derived KrasG12DHSCs efficiently
give rise to T-ALL, the T-ALL LSC population is initially
restricted to the thymus in primary recipient mice.
These results suggested that one or more secondary
mutations might have developed in a novel T-lymphoid
clone. Somatic NOTCH1 mutations are common in human
and murine T-ALL [25–28]. To determine if a similar
mechanism might contribute to the evolution of KrasG12D
HSCs to T-ALL LSCs, we performed Western blot analysis to
detect cleaved (activated) Notch1 protein. Cleaved Notch1
was observed in thymocytes from diseased primary recipients,
but not in bone marrow cells (Figure 7C), a finding that is
consistent with the secondary transplant data. Direct
sequencing around the PEST domain uncovered frameshift
mutations in exon 34 of Notch1 in thymocytes from five of six
animals transplanted with KrasG12D Flk2 LSK cells that
developed T-ALL, but no mutations in thymocytes from
control mice that received WT HSCs alone and remained
well. The presence of a somatically acquired Notch1 mutation
in a large fraction of the tumor provides a molecular
indication of clonality.
Thymic Abnormalities in KrasG12D Mice
The propensity of KrasG12D HSCs to generate T-ALL led us
to investigate the effects of KrasG12D expression in early T-
Figure 3. KrasG12D Does Not Lead to CMP Self-Renewal
Sorted CD45.1 CMPs were transplanted into lethally irradiated CD45.2
recipients.
(A) Spleens were harvested for CFU-S8 colony analysis 8 d after
transplantation of 104 KrasG12D or WT CMPs. Gross images and
hematoxylin/eosin stained sections are shown.
(B) Peripheral blood of animals analyzed 1 mo after transplantation of
104 KrasG12D or WT CMPs along with 106 CD45.1/CD45.2 heterozygous
nucleated bone marrow cells for radioprotection (Support). Costaining
with surface markers allowed detection of contributions to myeloid
(purple), B (blue), and T (black) lineages.
(C) Percentages of CMP-derived progeny within the indicated lineages
found in peripheral blood 1 mo after transplantation of WT (filled bars) or
KrasG12D (open bars) CMPs (n ¼ 4 in two independent sorts).
doi:10.1371/journal.pbio.1000059.g003
Figure 4. Transplanted KrasG12D Flk2 LSK Cells Outperform WT LSK Cells in Competitive Reconstitution
Lethally irradiated recipients (n¼ 4 in a single experiment) were transplanted with 500 each of KrasG12D and WT Flk2 LSK cells, then bled monthly until
sacrifice. Graphs show the proportion of graft-derived cells that came from the KrasG12D donor in circulating (A) T cell (CD3/CD5þ), (B) B cell (B220þ), and
(C) myeloid (Mac1/Gr1þ) populations. This was calculated by (1) gating for graft-derived cells (CD45.1 and CD45.1/CD45.2) within a lineage, and then (2)
determining the fraction of KrasG12D-derived cells (CD45.1) within this subset.
doi:10.1371/journal.pbio.1000059.g004
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lineage cells. Flow cytometry of the bone marrow revealed no
expansion of Lin Flk2þ IL-7Raþ c-kitint Sca1int common
lymphoid progenitors (Figure 8A) [29]. However, KrasG12D
mice demonstrated consistent thymic enlargement compared
to age-matched littermate controls, even prior to the onset of
T-ALL (Figure 8B). Immunophenotyping of primary thymo-
cytes demonstrated an essentially normal distribution of
CD4þ and CD8þ expression, with a slight trend toward an
increased number of CD4/CD8 double negative (DN) cells
(after excluding Mac1þ and Gr1þ infiltrating myeloid cells)
(Figure 8B). By contrast, further examination of the DN
compartment using the cell surface markers CD44 and CD25
uncovered skewed development in Kras mutant mice (Figure
8C). Together, these data demonstrate that oncogenic
KrasG12D perturbs thymic homeostasis, particularly in early
stages of thymocyte maturation.
Discussion
We find that oncogenic KrasG12D expression in HSCs
confers a strong in vivo growth advantage, increases
proliferation, and results in MPD and T-ALL. In MPD, as in
normal marrow, stem cell activity is restricted to the Flk2
LSK population, which represents less than 0.1% of nucleated
marrow cells. While pathologic behaviors of more mature
cells may contribute to tissue infiltration, anemia, and
organomegaly, self-renewal is confined to this very primitive
population. Therefore, hyperactive Ras signaling promotes
excess proliferation in multiple hematopoietic compartments
without immortalizing non–self-renewing cells. Similar data
have been described in murine models of MPD based on BCR-
ABL overexpression or loss of JunB, both of which also
deregulate cytoplasmic signaling networks [5,30]. By contrast,
recent experiments have provided direct evidence that some
oncogenic transcription factors allow committed myeloid
progenitors to acquire self-renewal ability [3,4]. Taken
together, studies of myeloid oncogenes performed to date
support the general idea that mutations that predominately
alter cytoplasmic signaling networks and those that affect
transcription factors controlling cell fate decisions comprise
discrete complementation groups for the fully transformed
phenotype [31,32].
Our limit dilution transplantation data demonstrate that
oncogenic Kras confers a dramatic growth advantage in the
HSC compartment. Under stringent conditions in which the
contribution of a single WT HSC can barely be detected, the
progeny of one (or at most three) KrasG12D HSC comprise a
substantial fraction of the hematopoietic compartment.
These studies provide direct experimental evidence that the
outgrowth of malignant cells in MPD can be attributed to
hyperactive Ras signaling in HSC. Our data suggest a
pathogenic model in which JMML or CMML is initiated by
a somatic mutation that deregulates Ras signaling in a single
HSC. This idea is consistent with limited data from human
patients and xenograft studies that implicate the HSC as the
cell of origin for JMML [33–38].
To begin to address the mechanism by which mutant HSCs
outgrow their WT counterparts, we analyzed the cell cycle in
KrasG12D Flk2 LSK cells and found they are preferentially in
cycle. The overexpression of cyclin D1 in KrasG12D cells we
observed is consistent with many prior studies in cultured cell
lines engineered to overexpress oncogenic Ras [39,40].
Intriguingly, HSCs in mice lacking D-type cyclins demon-
strate severe proliferative defects and accumulate in the G0
and/or G1 phases of the cell cycle [41]. If increased cyclin D1
levels conversely result in excessive proliferation of HSC,
then MPD in KrasG12D mice may be mediated in part by cyclin
D1, similar to the requirement for cyclin D1 in a model of
Ras-mediated breast cancer [42].
We demonstrate a substantial early growth advantage of
HSCs that express KrasG12D; however, it is also possible that
oncogenic Ras expression has a negative long-term impact on
HSC function. Increased proliferation or oncogenic stress
may ultimately detract from self-renewal capacity. Reduced
HSC fitness was observed in Pten/ mice, in which phospha-
tidylinositol 3-kinase signaling is hyperactive [43,44]. Similar
effects of KrasG12D are suggested by the reduced numbers of
HSCs in KrasG12D mice, although this finding could also
reflect changes in the composition of the Flk2 LSK
population or cell-extrinsic effects related to alteration of
the marrow microenvironment. The rapid demise of primary
KrasG12D mice from MPD, and of transplant recipients from
T-ALL, precluded serial transplantation experiments to test
the long term fitness of KrasG12D HSC. In addition, the 5-fold
discrepancy between HSC numbers that were measured by
flow cytometry versus limit dilution transplantation suggests
a defect in engraftment of KrasG12D HSC. This idea is
consistent with a prior report in which retroviral trans-
duction of mutant NRAS appeared to reduce engraftment
Figure 5. Transplanted KrasG12D Flk2 LSK Cells Induce MPD
Mice were analyzed 3 mo after transplantation with either KrasG12D or WT
Flk2 LSK cells for evidence of MPD (n¼ 3 WT, n¼ 6 KrasG12D in a single
experiment).
(A) Numbers of circulating leukocytes (WBC).
(B) Spleen weights.
(C) Percentages of myeloid cells (Mac1þ and/or Gr1þ) in the spleen.
(D) Percentages of erythroid precursors (nucleated and TER119þ) in the
spleen.
(E) A representative splenic section demonstrating infiltration by mature
myeloid cells (ring-shaped nuclei) and erythroblasts (small dense nuclei).
doi:10.1371/journal.pbio.1000059.g005
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potential [45], and with extensive data showing that prolif-
erating HSCs fail to engraft efficiently [46–50].
Despite the reduced number of HSC in the bone marrow of
KrasG12D mice, our data are not entirely consistent with the
idea that KrasG12D is a cell-intrinsic negative regulator of HSC
self-renewal. If it were, we would expect specific loss of
KrasG12D cells and outgrowth of WT or KrasLSL-G12D cells,
because conditional models using Mx1-Cre typically retain a
small pool of cells with the unrearranged locus [51,52].
However, we observed preferential retention of KrasG12D
cells, even within the diminishing Flk2 LSK compartment.
This observation suggests that residual WT HSCs are unable
to compensate for the reduced HSC number. Therefore, we
favor the hypothesis that the reduction in HSC number in
KrasG12D mice reflects a disordered bone marrow micro-
environment with reduced supportive capacity rather than a
purely cell-intrinsic effect of KrasG12D in HSC.
The natural history of hematologic disease was different in
primary KrasG12D mice than in recipients of transplanted
KrasG12D HSC. A subtle but important finding is that MPD is
established earlier in primary KrasG12D mice than in trans-
planted recipients. (Figure 5 and [13]; also see [16,53]). There
are several possible explanations for this observation. The
hematopoietic microenvironment in young mice may be
more permissive for MPD than the irradiated bone marrow of
an adult. Additionally, pIpC administration in Mx1-Cre mice
may quickly create a field of KrasG12D myeloid progenitors
that contributes to the rapid evolution of MPD in primary
mice through cytokine-mediated autocrine and/or paracrine
mechanisms [54]. It is also possible that nonhematopoietic
stromal cells in Mx1-Cre, KrasLSL-G12D mice express K-RasG12D
and contribute to the rapid onset of MPD in primary KrasG12D
mice.
The kinetics of MPD development relate directly to the
high frequency of T-ALL we observed in transplanted
recipients as compared to primary KrasG12D mice. The
apparent incidence of T-ALL is highly subject to selection
bias, because animals that die from MPD cannot be evaluated
for subsequent emergence of T-ALL. For example, we have
observed ;10%–15% of KrasG12D mice develop T-ALL on an
inbred C57BL/6 strain background (unpublished data), but
median time to death from MPD is shorter than the typical
latency of T-ALL, and lymphoid tumors exclusively appear in
mice with a relatively late onset of MPD. Similarly, we have
not observed spontaneous T-ALL in F1 (C57BL/63 129Sv/Jae)
mice, which die from MPD at a younger age than the C57BL/6
strain described here ([13] and unpublished data). In trans-
plant recipients, aggressive T-ALL arose in mice that also had
evidence of underlying MPD that was not yet severe enough
to kill the animal. Together, these observations suggest that
the attenuation of MPD in transplant recipients was central
to the apparent increase in the incidence of T-ALL in the
transplant setting.
Cooperation of hyperactive Ras and deregulated Notch
signaling in T-ALL has recently been shown [55–57]. Our data
extend these studies by demonstrating the remarkable
efficiency with which KrasG12D HSCs can initiate T-ALL,
and delineating how multiple cell types may participate in the
stepwise acquisition of oncogenic mutations in hematologic
cancers. In theMx1-Cre, KrasLSL-G12D model, T-ALL is initiated
by oncogenic Kras expression in HSC, but full transformation
occurs when cooperating Notch1 mutations arise in a T-
Figure 6. HSC Number and Proliferative Capacity in KrasG12D Mice
HSCs were analyzed in KrasG12D mice or WT littermates that were treated
with pIpC at 21 d of age and then sacrificed at 35 d of age.
(A) Total numbers of Flk2 LSK cells in KrasG12D mice (open bars) or WT
mice (filled bars) were quantified by flow cytometry in bone marrow (p,
0.001, t-test) and spleen (p , 0.01); total numbers (spleenþmarrow) are
also shown (p¼0.12). n¼6 mice per genotype, and error bars show SEM;
data are pooled from two independent experiments. Frequencies of Flk2
LSK cells among viable nucleated cells were multiplied by nucleated bone
marrow cell counts in femurs and tibias and then scaled to estimate total
bone marrow numbers using published distributions [75].
(B) Whole bone marrow from KrasG12D (open circles) or WT littermates
(filled circles) was tested for repopulating activity in a limit dilution
transplantation assay. The calculated values for frequencies of repopu-
lating units were 1 in 16,610 nucleated bone marrow cells (NMBC) for WT
marrow and 1 in 180,404 for KrasG12D marrow. Narrow lines designate
95% confidence intervals (1:7,338 to 1:37,598 for WT and 1:68,953 to 1:
471,998 for KrasG12D; frequencies in WT versus KrasG12D marrow are
significantly different with p¼ 0.0003 by two-tailed t-test). Outcomes of
individual experiments are described in Table S1.
(C) Mice that engrafted after transplantation with limiting numbers of
whole bone marrow cells (13 104 for WT, 13 105 for KrasG12D) were bled
at 2 mo to determine the percentage of circulating myeloid (Mac1/Gr1þ),
B-lineage (B220þ), and T-lineage (CD3/CD5þ) cells that were derived
from the transplanted marrow. Filled bars represent mice receiving WT
marrow (n¼ 2), open bars represent mice receiving KrasG12D marrow (n¼
3; error bars show SEM; note logarithmic scale).
doi:10.1371/journal.pbio.1000059.g006
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lineage cell. In this sense, both KrasG12D HSCs and the fully
transformed thymocytes can be considered different types of
malignant stem cells with distinct leukemogenic potentials.
One potential implication of these results is that the
initiating Kras mutation creates conditions favorable for
acquisition of cooperating mutations by increasing the size of
susceptible lymphoid progenitor pools and/or conferring
resistance to apoptotic signals during thymic selection.
KrasG12D appears to most greatly affect the DN population
that is characteristically undergoing TCR rearrangement,
selection, and proliferation [58,59]. Interestingly, K-RasG12D
protein expression may substitute for the pre-T cell receptor
rearrangement at this critical checkpoint, thereby allowing
propagation of thymocytes that would normally be edited
[60]. Consistent with this idea, a patient with impaired
lymphoid homeostasis and multiple lymphoid malignancies
was recently reported to have a germline NRASG13D mutation,
and oncogenic NRAS suppressed apoptosis of lymphocytes
after cytokine withdrawal [61]. By contrast, Kindler et al.
recently reported reduced thymic cellularity in Mx1-Cre,
Figure 7. Transplanted KrasG12D Flk2 LSK Cells Initiate T-ALLs That Contain Notch1 Mutations
(A) Flow cytometry of thymocytes harvested from moribund recipients of KrasG12D Flk2 LSK cells shows an abnormal accumulation of CD4/CD8 double
positive and immature CD8 single positive cells. Spleen histology demonstrates infiltration by monomorphic cells with open chromatin (hematoxylin/
eosin).
(B) Primary recipients (n¼5) received 500 KrasG12D Flk2 LSK cells with or without an equal number of WT Flk2 LSK cells after lethal irradiation (950 rad).
These primary recipients were euthanized 2–3 mo later, and 106 bone marrow cells or thymocytes were transferred into sublethally irradiated (450 rad)
secondary recipients (two per primary mouse). Sublethal irradiation selectively permits transfer of acute leukemia but not KrasG12D HSCs or MPD [13].
Thymocytes, but not bone marrow cells, transferred T-ALL.
(C) Cell lysates from thymocytes and bone marrow of animals euthanized 3 mo after transplantation with KrasG12D or WT HSCs were blotted with an
antibody specific for cleaved Notch1. Three independent primary recipients are shown. Sequence analysis demonstrates frameshift mutations near the
PEST domain of Notch1 in thymocytes from five of six mice that received KrasG12D HSC, but not in recipients receiving WT HSCs alone (reference
sequence from GenBank [http://www.ncbi.nlm.nih.gov/Genbank] accession number NM_008714).
doi:10.1371/journal.pbio.1000059.g007
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KrasG12D mice [56]. We speculate that the proliferative effects
of K-RasG12D in the T cell compartment were obscured in
those studies by the short interval between pIpC injection,
which induces systemic interferon production, and histologic
analysis.
The idea that patients may harbor a variety of genetically
distinct LSC is consistent with studies of patients with
chronic myeloid leukemia in blast transformation [62], and
has important therapeutic implications. The need to elimi-
nate partially transformed but self-renewing cells, like
KrasG12D HSCs, will depend on their propensity to initiate a
life-threatening disease. Targeted therapies that are directed
against onco-proteins such as K-RasG12D will effectively
eliminate premalignant clones only if the targeted lesions
are initiating rather than secondary mutations. For example,
inhibition of Notch signaling is an attractive therapeutic
strategy for T-ALL that is being investigated in the clinic.
However, if these cancers arise from aberrant HSCs that do
not contain a NOTCH1 mutation and are not eradicated by
treatment, relapse could occur through the acquisition of
distinct cooperating mutations in a self-renewing preleuke-
mic population. Consistent with this idea, studies of human
T-ALL suggest that NOTCH1 mutation occurs as a secondary
mutation in at least some cases, with some patients
Figure 8. Abnormal T-lymphoid Development in KrasG12D Mice
(A) Enumeration of Lin Flk2þ IL-7Raþ c-kitint Sca1int common lymphoid progenitors (CLPs) in bone marrow of WT and KrasG12D mice. A typical
comparison and gating strategy is shown, with the far right panel showing expression of c-kit and Sca1 in CLPs (black dots) compared to the larger
population of Lin cells (gray dots). CLP frequencies are graphed (n ¼ 5 WT and 6 KrasG12D; error bars show SEM and difference is not statistically
significant by unpaired t-test).
(B) Enlarged thymi in 7-wk-old KrasG12D mice compared with WT littermates; photograph shows a typical example, and graph shows data from a
representative cohort (n¼ 3 mice and error bars show standard deviation; p , 0.05).
(C) Flow cytometry of primary thymocytes for expression of CD4 and CD8, and also CD25 and CD44 expression within DN (CD4 CD8) cells; figure
shows a representative example. Myeloid cells were excluded using Mac1 and Gr1 staining. Graph represents the frequency of thymocytes within in the
live gate in DN, double positive (CD4þD8þ, DP), and CD4 or CD8 single positive cells (n¼3 mice per genotype and error bars show SEM; p . 0.05 for all
populations. Data are representative of three independent experiments).
doi:10.1371/journal.pbio.1000059.g008
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developing recurrent disease having distinct NOTCH1 alleles
[63].
Finally, our data have implications for understanding the
nature of cancer stem cell populations in nonhematopoietic
malignancies. KRAS is the most frequent target of dominant
oncogenic mutations in human cancer, and it is particularly
important in carcinomas of the lung, pancreas, and colon.
Analogous cancers arise in strains of mice expressing condi-
tional oncogenic Kras alleles in these tissues [64–68].
Importantly, whereas oncogenic Kras expression efficiently
initiates tumorigenesis in murine lung and pancreas, colon
cancer is observed only when the tumor suppressor Apc is
inactivated as well [68]. These data are consistent with studies
of human patients, which imply that KRAS mutation occurs
early in pancreatic cancer but typically after APC mutation in
colon carcinoma [69–71]. Lung cancer in KrasG12D mice
appears to be initiated in a distinct bronchio-alveolar stem
cell population [72]. On the basis of these observations and
our data, we speculate that, like HSCs, cells initiating
pancreatic and lung cancer will possess inherent self-renewal
potential, and that KRAS mutations only contribute to colon
tumorigenesis in cells that have already acquired a mutation
that enhances self-renewal. Uncovering specific proteins and
pathways that are essential for the self-renewal and survival of
Kras mutant cancer stem cell populations may reveal novel
targets for therapeutic intervention in a variety of human
cancers.
Materials and Methods
Ethics statement. All animals were handled in strict accordance
with good animal practice as defined by the relevant national and
local animal welfare bodies, and all animal work was approved by the
institutional animal research committee (University of California,
San Francisco IACUC).
Mouse strains. Animals were housed in a barrier facility at the
University of California, San Francisco. All mice were of the C57BL/6
strain. As described [13], 21-d-old Mx1-Cre, KrasLSL-G12D were injected
IP with 250 lg pIpC (Sigma). ROSA26 LSL-YFP reporter mice were a
gift from C. Lowell. Ptprc (CD45) congenic mice were from Jackson
Labs.
Colony assays. To assay CFU-GM, nucleated bone marrow cells
(105) or splenocytes (23 105) were suspended in 1 ml methylcellulose
medium (M3231, StemCell Technologies) with 10 ng/ml murine GM-
CSF (PeproTech). Colonies were counted after 8 d. To assay Flk2
LSK cells, 100 sorted cells were plated in 1 ml methylcellulose
medium (M3434, StemCell Technologies), which is provided contain-
ing IL-3, IL-6, stem cell factor, and erythropoietin, and incubated at
37 8C for 14 d. For Kras genotyping, individual colonies were picked
with a 10 ll pipette and frozen overnight in 10 ll ddH2O prior to
PCR analysis [13].
Flow cytometry. Flow cytometry was performed as described
[21,24]. Staining was carried out in FACS Staining Buffer (FSB;
HBSS with 2% heat inactivated FCS) at 0 8C unless otherwise stated.
HSCs were defined as Lin/lo Sca1þ c-kitþ Flk2, and CMP as Lin/lo
Sca1 c-kitþ CD34þ FccR. Antibodies were from eBioscience except
as specified. To identify HSCs, cells were first stained for 1 h with
unconjugated lineage antibodies: CD3 (17A2, BioLegend); CD4
(RM4–5); CD5 (53–7.3); CD8 (53–6.7); B220 (RA3-6B2); Ter119
(TER-119); Mac1 (M1/70); Gr1 (RB6-8C5). Cells were washed then
incubated for 30 min with TriColor goat-anti-rat F(ab9)2 (Invitrogen)
and murine IgG (Sigma). Cells were washed again, stained for 30 min
with Pacific Blue anti-Sca1 (D7, BioLegend); APC anti-c-kit (2B8,
BioLegend); PE anti-Flk2 (A2F10, BioLegend); and 7-AAD (Sigma) 5
lg/ml for dead cell exclusion. IL-7Ra was detected using a PE
conjugate (eBioscience). In this case, or when analyzing YFPþ cells,
Flk2 was detected with biotinylated anti-Flk2 and APC-Alexa Fluor
750 streptavidin (Invitrogen). We found no difference in Flk2 LSK
staining when Mac1þ cells were identified an on independent
channel but not excluded. For myeloid progenitor analysis, PE
anti-Flk2 was replaced with PE anti-FccRII/III (93) and FITC anti-
CD34 (RAM34), and cells were stained for an additional 30 min prior
to analysis. Mature cells were assigned lineage using Pacific Blue
anti-Mac1 and anti-Gr1 (myeloid), FITC anti-CD3 and anti-CD5 (T),
and PE anti-B220 (B). T cell subsets in mice with T-ALL were
distinguished with Pacific Orange anti-CD4 (Invitrogen), APC anti-
CD8, FITC anti-CD3, and PE anti-CD5. To discern origin of cells in
chimeric mice, antibodies to CD45.1 (A20; PE-Cy7) and CD45.2 (104;
Alexa Fluor 700) were added. Primary thymocytes were analyzed
with PE-Cy7 anti-CD4, Alexa 647 anti-CD8, PE anti-CD25, Pacific
Blue anti-CD44, and FITC anti-Mac1 and anti-Gr1.
Prior to sorting, c-kitþ cells were enriched with anti-CD117
microbeads and an AutoMACS (Miltenyi). Cell sorting was performed
on a FACSAria and flow cytometry on an LSRII, both using FACSDiva
software (BD). Data were analyzed using FlowJo software (TreeStar).
Transplantation. Recipients received a single fraction of 950 rads
for lethal irradiation, or 450 rads for sublethal irradiation, from a
cesium source. Donor cells were prepared in 100 to 200 ll of FSB, and
injected retro-orbitally into anesthetized mice. Recipients received
water with neomycin and polymyxin for 2 wk. Blood counts were
monitored monthly using a Hemavet 950FS (Drew Scientific).
Limit dilution was performed as described [73]. Lethally irradiated
recipients were transplanted with 1 3 104, 3 3 104, or 1 3 105
nucleated bone marrow cells along with 106 unfractionated WT bone
marrow cells for radioprotection. Peripheral blood was analyzed
monthly by flow cytometry; mice with detectable engraftment in
myeloid, B and T lineages 2 mo after transplantation were scored as
positive and L-Calc software (StemCell Technologies) was used for
statistical analysis.
For the CFU-S8 assay, lethally irradiated mice received 10
5 CMPs
without support cells. Spleen colonies were observed 8 d later by
gross examination at harvest and after 48 h fixation in 10% formalin.
Sections were stained with hematoxylin and eosin.
Notch1 analysis. Cells were lysed in 1% NP-40 with 30 mM NaF, 30
mM b-glycerophosphate, 20 mM Na4P2O7, 1 mM Na3VO4, and
Complete (Roche) and analyzed after SDS-PAGE using cleaved
Notch1 and b-actin antibodies (Cell Signaling). Genomic DNA was
PCR-amplified sequenced bidirectionally using 59-ATAGCAT-
GATGGGGCCACTA-39 and 59-GCCTCTGGAATGTGGGTGAT-39.
Cell cycle analysis. Staining with 7-AAD and pyronin Y was
performed as described [74] in nucleic acid staining solution (NASS;
0.1M phosphate-citrate buffer [pH 6.0] [Sigma], 5mM EDTA, 0.15M
NaCl, 0.5% BSA), with 0.02% saponin (Sigma). Nucleated bone
marrow cells were stained for 30 min with FITC lineage antibodies
(CD3, CD4, CD5, CD8, B220, Ter119, and Gr1), Pacific Blue anti-Sca1,
unconjugated anti-CD16/32 (2.4G2, UCSF hybridoma core), and
biotinylated anti-Flk2. Cells were washed and then stained with
APC-Alexa Fluor 750 streptavidin. Cells were washed again and
resuspended in 500 ll of NASS with 1 lg/ml 7-AAD (Sigma), and
incubated at room temperature for 30 min, then on ice for 5 min.
Pyronin Y (Sigma) was then added to 1 lg/ml, and cells were
incubated for an additional 10 min before being washed and
resuspended in 200 lL of FSB. Cells were finally stained with APC
anti-c-kit and FITC anti-Mac1. Differences in the quiescent fraction
of HSCs were analyzed using an unpaired t-test.
Quantitative real-time PCR. The assay was performed as described
[50]. Flk2 KLS cells from animals pooled by genotype were double-
sorted directly into RNA binding/lysis buffer from the RNEasy kit
(Qiagen), and total RNA was extracted per instructions. First strand
cDNA synthesis was performed using a SuperScript III kit (Invitro-
gen) per manufacturer’s instructions. Reactions were performed in
an ABI-7900 sequence detection system using SYBR green according
to manufacturer’s instructions (Applied Biosystems). Each amplifica-
tion was performed in 10 ll with a template cDNA equivalent of 100
sorted HSCs. Each sample was tested in triplicate with each primer
pair, and normalized to b-actin expression. Due to limiting numbers
of doubly sorted cells, final cell purity was not analyzed; however the
staining characteristics of c-kit-enriched and singly sorted cells are
presented in Figure S1.
Poisson statistics. To analyze repopulation by a single HSC, we
identified a cohort of mice receiving a cell dose yielding engraftment
in only 50% of recipients. The Poisson distribution indicates that the
probability of a mouse receiving k HSCs is given by
f ðk; nÞ ¼ n
ken
k!
;
where n is the average HSC number per mouse. The average that
yields k¼ 0 HSC at a rate of 0.5 is given by 0.5¼ en, which is solved to
give n ¼ 0.693. Using this value for the average number of HSC per
mouse, the Poisson distribution can be used to estimate the
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likelihood of any mouse receiving a given number of HSC: f(0)¼ eln 2
¼ 0.5; f(1)¼ (ln 2)eln 2¼ 0.346; f(2)¼ 1/2 (ln 2)2eln 2¼ 0.120; f(3)¼ 1/6
(ln 2)3eln 2¼ 0.028. The proportion of mice expected to receive four
or more HSCs is the remainder, 1  (0.5 þ 0.346 þ 0.12 þ 0.028) ¼
0.006, or 0.6%.
Supporting Information
Figure S1. Purity of Cells Sorted for RNA Purification
Cells expressing c-kit were enriched by magnetic bead isolation, then
doubly sorted by FACS. FACS data for the first and second sorts for
typical examples of WT and KrasG12D mice are shown.
Found at doi:10.1371/journal.pbio.1000059.sg001 (740 KB TIF).
Figure S2. Flk2 LSK Cell Number in 8-wk-Old KrasG12D Mice
Flow cytometry was performed to enumerate Flk2 LSK cells in bone
marrow (n¼4; p, 0.05) and spleens (n¼6; p, 0.05) harvested from 8-
wk-old KrasG12D or WT mice. Data were analyzed as in Figure 2.
Combined numbers in marrow and spleen were not significantly
different between genotypes (p ¼ 0.27). Data are pooled from two
independent experiments; error bars show standard error of the mean
(SEM). Statistical significance was evaluated with the unpaired t-test.
Found at doi:10.1371/journal.pbio.1000059.sg002 (80 KB TIF).
Figure S3. KrasG12D HSCs Dominate the Stem Cell Compartment by 3
mo after Transplantation
Mice transplanted with 500 CD45.1 KrasG12D and 500 CD45.1/CD45.2
WT HSCs were sacrificed (A) 2 mo (n ¼ 6) or (B) 3 mo (n ¼ 2) after
transplantation, and their chimerism was assessed by flow cytometry.
The percentage of graft cells derived from the KrasG12D HSCs is
shown for Flk2 LSK cells (black bars), CMPs (dark grey bars),
granulocyte-macrophage progenitors (GMP, light grey bars), and
mature (Mac1/Gr1þ) circulating myeloid cells (open bars). GMPs were
defined as Lin/lo Sca1 c-kitþ FccRII/IIIþ. Animals lacking any graft-
derived contribution to the HSC compartment have been omitted.
Found at doi:10.1371/journal.pbio.1000059.sg003 (168 KB TIF).
Table S1. Outcomes of Individual Limit Dilution Transplantation
Experiments
The indicated numbers of mice were transplanted with 10,000,
30,000, or 100,000 nucleated bone marrow cells, and the proportions
with detectable multilineage engraftment were determined 2 mo
later. The number of repopulating units was calculated using the
totals from these four experiments with L-Calc software (StemCell
Technologies).
Found at doi:10.1371/journal.pbio.1000059.st001 (47 KB PDF).
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